1.
Rev Med Chil
; 143(7): 895-904, 2015 Jul.
Article
in Spanish
| MEDLINE
| ID: mdl-26361027
ABSTRACT
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.
Subject(s)
Pulmonary Embolism/therapy , Thrombolytic Therapy/methods , Fibrinolytic Agents/classification , Fibrinolytic Agents/therapeutic use , Humans , Risk Factors , Thrombectomy , Treatment Outcome
2.
Rev. méd. Chile
; 143(7): 895-904, jul. 2015. tab
Article
in Spanish
| LILACS
| ID: lil-757915
ABSTRACT
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.
